Alberto Miceli
Overview
Explore the profile of Alberto Miceli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Santo G, Miceli A
Eur J Nucl Med Mol Imaging
. 2024 Aug;
51(13):3813-3814.
PMID: 39093428
No abstract available.
2.
Dondi F, Miceli A, Rovera G, Feudo V, Battisti C, Rondini M, et al.
Bioengineering (Basel)
. 2024 Jul;
11(7).
PMID: 39061796
Introduction: The term theragnostic refers to the combination of a predictive imaging biomarker with a therapeutic agent. The promising application of prostate-specific membrane antigen (PSMA)-based radiopharmaceuticals in the imaging and...
3.
Miceli A, Liberini V, Pepe G, Dondi F, Vento A, Jonghi Lavarini L, et al.
Diagnostics (Basel)
. 2024 May;
14(10).
PMID: 38786300
Background: Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein overexpressed on the surface of tumor cells in most of the patients affected by prostate adenocarcinoma (PCa). However, PSMA...
4.
Guglielmo P, Alongi P, Baratto L, Conte M, Abenavoli E, Buschiazzo A, et al.
Cancers (Basel)
. 2024 Feb;
16(4).
PMID: 38398230
(1) Background: Thyroid cancer (TC) is often treated with surgery followed by iodine-131. Up to 50% of the instances of TC lose their avidity to I, becoming more aggressive. In...
5.
Porcari A, Fontana M, Canepa M, Biagini E, Cappelli F, Gagliardi C, et al.
Circulation
. 2024 Feb;
149(15):1157-1168.
PMID: 38328945
Background: The extent of myocardial bone tracer uptake with technetium pyrophosphate, hydroxymethylene diphosphonate, and 3,3-diphosphono-1,2-propanodicarboxylate in transthyretin amyloid cardiomyopathy (ATTR-CM) might reflect cardiac amyloid burden and be associated with outcome....
6.
Nappi A, Santo G, Jonghi-Lavarini L, Miceli A, Lazzarato A, La Torre F, et al.
Hematol Rep
. 2024 Jan;
16(1):32-41.
PMID: 38247994
Fluorine-18 fluorodeoxyglucose ([F]FDG) is nowadays the leading positron emission tomography (PET) tracer for routine clinical work-ups in hematological malignancies; however, it is limited by false positive findings. Notably, false positives...
7.
Rizzo A, Miceli A, Racca M, Bauckneht M, Morbelli S, Albano D, et al.
Pharmaceuticals (Basel)
. 2023 Dec;
16(12).
PMID: 38139791
Several studies have examined the use of positron emission tomography (PET) using [Ga]Ga-radiolabeled fibroblast-activation protein inhibitors (FAPi) across multiple subtypes of head and neck cancer (HNC). The purpose of the...
8.
Guglielmo P, Alongi P, Baratto L, Abenavoli E, Buschiazzo A, Celesti G, et al.
Life (Basel)
. 2023 Sep;
13(9).
PMID: 37763225
FAPI-based radiopharmaceuticals are a novel class of tracers, mainly used for PET imaging, which have demonstrated several advantages over [F]FDG, especially in the case of low-grade or well-differentiated tumors. We...
9.
Bauckneht M, Miceli A, Signori A, Albano D, Capitanio S, Piva R, et al.
Eur Radiol
. 2023 Mar;
33(5):3343-3353.
PMID: 36892650
Objectives: Increased detection of prostate cancer (PCa) recurrences using [Ga]Ga-PSMA-11 PET/CT has been reported by adding forced diuresis or late-phase imaging to the standard protocol. However, the combination of these...
10.
Bauckneht M, Marini C, Cossu V, Campi C, Riondato M, Bruno S, et al.
J Transl Med
. 2023 Jan;
21(1):3.
PMID: 36600265
Background: Positron Emission Tomography (PET) imaging with Prostate-Specific Membrane Antigen (PSMA) and Fluorodeoxyglucose (FDG) represent promising biomarkers for risk-stratification of Prostate Cancer (PCa). We verified whether the expression of genes...